Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Fadi Haddad(Trinity Health), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Walid Macaron(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Kelly S. Chien, Naval Daver(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Jennifer Thankachan(The University of Texas MD Anderson Cancer Center), Pinaki P. Banerjee(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Kun Hee Kim(Ulsan College), Monica Kwari(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), Xianli Jiang(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Ricardo Delumpa(The University of Texas MD Anderson Cancer Center)
The Lancet Haematology
November 16, 2022
Cited by 242


Related Papers